FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:136-137 January 13, 2000 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Samama, M. M. PubMed Citation

To the Editor: Samama et al. (Sept. 9 issue)¹ compared enoxaparin with saline placebo for the prevention of venous thromboembolism in acutely ill medical patients. I was surprised that the study drug was compared with a placebo, since venous thromboembolism is a potentially life-threatening illness and since those receiving the placebo would have a higher incidence of morbidity. The authors state, "The use of a placebo group was considered to be ethically justifiable because the incidence of venous thromboembolism among such patients had not been established, there was no established method of thromboprophylaxis for these patients, and patients with a . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Avorn, J., Winkelmayer, W. C. (2004). Comparing the Costs, Risks, and Benefits of Competing Strategies for the Primary Prevention of Venous Thromboembolism. Circulation 110: IV-25-IV-32 [Abstract] [Full Text]